Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine

Turcan, Sevin, Fabius, Armida W. M., Borodovsky, Alexandra, Pedraza, Alicia, Brennan, Cameron, Huse, Jason, Viale, Agnes, Riggins, Gregory J. +1 more·2013·Oncotarget

DOI 10.18632/oncotarget.1412

Cited by (242)

Items 101–200 of 242

Current therapeutic approaches to diffuse grade II and III gliomas
Alberto Pïcca, Giulia Berzero, Marc Sanson · 2018 · Therapeutic Advances in Neurological Disorders
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
Tina Paradžik, Cecilia Bandini, Elisabetta Mereu, María Labrador, Elisa Taìana, Nicola Amodio, Antonino Neri, Roberto Piva · 2021 · Cancers
Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
Sanne Venneker, Alwine B. Kruisselbrink, Inge H. Briaire‐de Bruijn, Yvonne de Jong, André J. van Wijnen, Erik H.J. Danen, Judith V.M.G. Bovée · 2019 · Cancers
TERT and DNMT1 expression predict sensitivity to decitabine in gliomas
Jong‐Whi Park, Felix Sahm, Bianca Steffl, Isabel Arrillaga‐Romany, Daniel P. Cahill, Michelle Monje, Christel C. Herold‐Mende, Wolfgang Wick, Şevin Turcan · 2020 · Neuro-Oncology
Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1 -Mutant Gliomas
Sichen Li, Reshmi Chowdhury, Fei Liu, Arthur P. Chou, Tie Li, Reema R. Mody, Jerry J. Lou, Wei‐Dong Chen, Jean Reiss, Horacio Soto et al. · 2014 · Clinical Cancer Research
Magnetic resonance analysis of malignant transformation in recurrent glioma
Llewellyn E. Jalbert, Evan Neill, Joanna J. Phillips, Janine Lupo, Marram P. Olson, Annette M. Molinaro, Mitchel Stuart Berger, Susan Marina Chang, Sarah J. Nelson · 2016 · Neuro-Oncology
Current and Investigational Drug Strategies for Glioblastoma
M. Ajaz, Sarah Jefferies, L. Brazil, Colin Watts, Anthony J. Chalmers · 2014 · Clinical Oncology
Molecular profiling of gliomas: potential therapeutic implications
Agustí Alentorn, Alberto Durán-Peña, Sandeep C. Pingle, David Eric Piccioni, Ahmed Idbaïh, Santosh Kesari · 2015 · Expert Review of Anticancer Therapy
Deregulated proliferation and differentiation in brain tumors
Fredrik J. Swartling, Matko Čančer, Aaron Frantz, Holger Weishaupt, Anders I. Persson · 2014 · Cell and Tissue Research
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
Jong‐Whi Park, Şevin Turcan · 2019 · Cancers
IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives
Fabiana Crispo, Michele Pietrafesa, Valentina Condelli, Francesca Maddalena, Giuseppina Bruno, Annamaria Piscazzi, Alessandro Sgambato, Franca Esposito, Matteo Landriscina · 2020 · Molecules
Decitabine Nanoconjugate Sensitizes Human Glioblastoma Cells to Temozolomide
Yi Cui, Asia Naz, David H. Thompson, Joseph Irudayaraj · 2015 · Molecular Pharmaceutics
5-Azacitidine in patients with IDH1/2-mutant recurrent glioma
Laetitia Federici, Laurent Capelle, Maxime Annereau, Franck Bielle, Christophe Willekens, Caroline Dehais, Florence Laigle–Donadey, Khê Hoang‐Xuan, Jean‐Yves Delattre, Ahmed Idbaïh et al. · 2020 · Neuro-Oncology
Epidrugs in the Therapy of Central Nervous System Disorders: A Way to Drive on?
Marina G. Gladkova, Este Leidmaa, Elmira A. Anderzhanova · 2023 · Cells
Further understanding of the pathology of glioma: implications for the clinic
Sandra Ines Camelo-Piragua, Santosh Kesari · 2016 · Expert Review of Neurotherapeutics
Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas
Magimairajan Vanan, D. Alan Underhill, David D. Eisenstat · 2017 · Neurotherapeutics
Lineage Plasticity in Cancer: The Tale of a Skin-Walker
Archana P. Thankamony, Ayalur Raghu Subbalakshmi, Mohit Kumar Jolly, Radhika Nair · 2021 · Cancers
Integrated analysis of single-cell chromatin state and transcriptome identified common vulnerability despite glioblastoma heterogeneity
Ramya Raviram, Anugraha Raman, Sebastian Preißl, Jianfang Ning, Shaoping Wu, Tomoyuki Koga, Kai Zhang, Cameron Walter Brennan, Chenxu Zhu, Jens Luebeck et al. · 2023 · Proceedings of the National Academy of Sciences
Translational genomics of sinonasal cancers
Mario A. J. A. Hermsen, Cristina Riobello, Rocío García‐Marín, Virginia N. Cabal, Laura Suárez–Fernández, Fernando López, José Luís Llorente · 2019 · Seminars in Cancer Biology
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies
María Belén Garcia-Fabiani, Santiago Haase, Andrea Comba, Stephen V. Carney, Brandon L. McClellan, Kaushik Banerjee, Mahmoud S. Alghamri, Syed Mohd Faisal, Padma Kadiyala, Felipe Javier Núñez et al. · 2021 · Frontiers in Oncology
Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies
Matthew S. Waitkus, Hai Yan · 2020 · Clinical Cancer Research
Characterizing crosstalk in epigenetic signaling to understand disease physiology
Joanna K. Lempiäinen, Benjamin Aaron Garcia · 2023 · Biochemical Journal
Epigenetic Modification and Differentiation Induction of Malignant Glioma Cells by Oligo-Fucoidan
Chien-Huang Liao, I‐Chun Lai, Hui-Ching Kuo, Shuang‐En Chuang, Hsin‐Lun Lee, Jacqueline Whang‐Peng, Chih‐Jung Yao, Gi‐Ming Lai · 2019 · Marine Drugs
IDH Mutations in Chondrosarcoma: Case Closed or Not?
Sanne Venneker, Judith V.M.G. Bovée · 2023 · Cancers
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations
Pasquale Persico, Elena Lorenzi, Agnese Losurdo, Angelo Dipasquale, Antonio Di Muzio, Pierina Navarria, Federico Pessina, Letterio Salvatore Politi, Giuseppe Lombardi, Armando Santoro et al. · 2022 · Cancers
Targeting Glioma Stem Cells: Therapeutic Opportunities and Challenges
Asma Mahdi, Mohamed Aittaleb, Fadel Tissir · 2025 · Cells
Investigational new drugs for brain cancer
Verena Staedtke, Ren-Yuan Bai, John Laterra · 2016 · Expert Opinion on Investigational Drugs
Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential
Patricia D.B. Tiburcio, David L. Gillespie, Randy L. Jensen, Eric L. Huang · 2020 · Journal of Neuro-Oncology
Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells
Yang Cao, Guoqiang Qiu, Hao-qing Wu, Zhilin Wang, Yan Lin, Wei Wu, Xiaobao Xie, Weiying Gu · 2016 · Molecular Medicine Reports
Identification of endometrial cancer methylation features using combined methylation analysis methods
Michael P. Trimarchi, Pearlly S. Yan, Joanna Louise Groden, Ralf A. Bundschuh, Paul J. Goodfellow · 2017 · PLoS ONE
The epigenetic mechanisms involved in the treatment resistance of glioblastoma
Aanya Shahani, Hasan Slika, Ahmad Elbeltagy, Alexandra Lee, Christopher Peters, Toriyn Dotson, Divyaansh Raj, Betty Tyler · 2025 · Cancer Drug Resistance
Isocitrate dehydrogenase mutations in chondrosarcoma
Georges Azzi, Michel Velez, Maria Cecília Mathias-Machado · 2014 · Current Opinion in Oncology
Extent of Resection Versus Molecular Classification
Victoria Elizabeth Clark, Daniel P. Cahill · 2018 · Neurosurgery Clinics of North America
Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer
Jonathan Robert Brody, Cinthya S. Yabar, Mahsa Zarei, Joseph Bender, Lynn McCormick Matrisian, Lola Rahib, Craig Heartwell, Kimberly Mason, Charles J. Yeo, Stephen C. Peiper et al. · 2016 · Cancer Biology & Therapy
Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
Yuyang Pang, Tingxun Lu, Zijun Yidan Xu-Monette, Ken H. Young · 2023 · International Journal of Molecular Sciences
HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma
Matthew C. Garrett, Rebecca Albano, Troy Carnwath, Lubayna S. Elahi, Catherine A. Behrmann, Merissa Pemberton, Daniel Woo, Eric Justin O'Brien, Brett VanCauwenbergh, John Peter Perentesis et al. · 2023 · Scientific Reports
Chinese herbal medicine Xiaoji decoction inhibited growth of lung cancer cells through AMPKα-mediated inhibition of Sp1 and DNA methyltransferase 1
Shunyu Zhao, Jingjing Wu, Qing Tang, Fang Zheng, Lijun Yang, Yuqin Chen, Liuning Li, Swei Sunny Hann · 2016 · Journal of Ethnopharmacology
IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis
Kamila Rosiak, Maciej Smolarz, Wojciech J. Stec, Joanna Peciak, Dawid P. Grzela, Marta Winiecka-Klimek, Ewelina Stoczyńska-Fidelus, Barbara Krynska, Sylwester Piaskowski, Piotr Rieske · 2016 · PLoS ONE
Genomic discoveries in adult astrocytoma
Joanna Wang, Chetan Bettegowda · 2015 · Current Opinion in Genetics & Development
Epigenetic Drugs and Their Immune Modulating Potential in Cancers
Yingying Liang, Şevin Turcan · 2022 · Biomedicines
Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypes
Yang Chen, Zhen Gao, Bingcheng Wang, Rong Xu · 2016 · BMC Genomics
Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells
Sara Haddock, Tyler Joseph Alban, Şevin Turcan, Hana Husic, Eric Rosiek, Xiaoxiao Ma, Yuxiang Wang, Tejus Bale, Alexis Desrichard, Vladimir Makarov et al. · 2022 · Neoplasia
Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents
Eytan M. Stein, Katharine E. Yen · 2017 · Annual Review of Cancer Biology
DNA methylation in adult diffuse gliomas
Véronique Leblanc, Marco A. Marra · 2016 · Briefings in Functional Genomics
Branched-chain amino acid transaminase 1 regulates glioblastoma cell plasticity and contributes to immunosuppression
Pavle Boskovic, Nathalie Wilke, Ka-Hou Man, Peter Lichter, Liliana Francois, Bernhard Radlwimmer · 2023 · Neuro-Oncology
Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment
Swagata Adhikari, Deblina Guha, Chitra Mohan, Shravanti Mukherjee, Jessica K. Tyler, Chandrima Das · 2022 · Sub-cellular biochemistry/Subcellular biochemistry
Non-canonical roles for metabolic enzymes and intermediates in malignant progression and metastasis
Demond Williams, Barbara Fingleton · 2019 · Clinical & Experimental Metastasis
An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors
Sara Verdura, Elisabet Cuyàs, Jesús Lozano‐Sánchez, Cristian Bastidas-Velez, Laura Llorach-Parés, Salvador Fernández‐Arroyo, Anna Hernández‐Aguilera, Jorge Joven, Alfons Nonell‐Canals, Joaquim Bosch‐Barrera et al. · 2018 · Carcinogenesis
Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening
Zhe Duan, Jingqiu Liu, Liping Niu, Jun Wang, Mingqian Feng, Hua Chen, Cheng Luo · 2019 · Bioorganic & Medicinal Chemistry
IDH2-Mutated Sinonasal Tumors: A Review
Bayan Alzumaili, Peter M. Sadow · 2022 · Advances in Anatomic Pathology
IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH ‐mutant astrocytoma PMMRDIA : a systematic review
Olfat Ahmad, Tahani M. Ahmad, Stefan Michael Pfister · 2024 · Molecular Oncology
The epigenetic dysfunction underlying malignant glioma pathogenesis
Sharvari Dharmaiah, Jason T. Huse · 2022 · Laboratory Investigation
Targeting DNA Methylation Machinery in Pediatric Solid Tumors
Camilla Cristalli, Katia Scotlandi · 2024 · Cells
Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas
Marina da Costa Rosa, Alex Shimura Yamashita, Gregory Joseph Riggins · 2021 · Neuro-Oncology
Emerging Interplay of Genetics and Epigenetics in Gliomas: A New Hope for Targeted Therapy
Raymund L.M. Yong, Nadejda M. Tsankova · 2014 · Seminars in Pediatric Neurology
Metabolic enzymes: key modulators of functionality in cancer stem-like cells
Bowen Dong, Guangming Qin, Yan Luo, Jianshan Mao · 2016 · Oncotarget
Anaplastic gliomas in adults: an update
Cristina Izquierdo, Bastien Joubert, François Ducray · 2017 · Current Opinion in Oncology
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas
Ourania Romanidou, Vassiliki Kotoula, George Fountzilas · 2018 · Cancer Genomics & Proteomics
Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors
Yosuke Kitagawa, Ami Kobayashi, Daniel P. Cahill, Hiroaki Wakimoto, Shota Tanaka · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC
Jian Wang, Zhan-guo Zhang, Zeyang Ding, Wei Dong, Hui-fang Liang, Liang Chu, Bi-xiang Zhang, Xiaoping Chen · 2018 · Journal of Surgical Research
Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma
Hazel Anne Rogers, Rebecca J. Chapman, Holly Kings, Julie Allard, Jodie Barron-Hastings, Kristian W. Pajtler, Martin Sill, Stefan Michael Pfister, Richard Guy Grundy · 2018 · Oncotarget
Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis
Patricia D.B. Tiburcio, Bing Xiao, Shauna Berg, Sydney Asper, Sean B. Lyne, Yan Zhang, Xingen Zhu, Hai Yan, L. Eric Huang · 2017 · Acta Neuropathologica
Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy
Luyuan Li, Josiane E. Eid, Ana Cristina Paz, Jonathan C. Trent · 2017 · BioDrugs
Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer
Louis Y. El Khoury, Shuang Fu, Ryan A. Hlady, Ryan T. Wagner, Liguo Wang, Jeanette E. Eckel‐Passow, Erik P. Castle, Melissa Stanton, Robert Houston Thompson, Alexander Scott Parker et al. · 2021 · Clinical Epigenetics
In vivo efficacy of decitabine as a natural killer cell–mediated immunotherapy against isocitrate dehydrogenase mutant gliomas
Xiaoran Zhang, Wi Jin Kim, Aparna V. Rao, Emade Jaman, Christopher P. Deibert, Poorva Sandlesh, Katharine Krueger, Jordan C. Allen, Nduka M. Amankulor · 2022 · Neurosurgical FOCUS
From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy
Emanuela Di Gregorio, Gianmaria Miolo, Asia Saorin, Agostino Steffan, Giuseppe Corona · 2021 · International Journal of Molecular Sciences
Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas
Nikolaus von Knebel Doeberitz, Daniel Paech, Dominik Sturm, Stefan Pusch, Şevin Turcan, Yogen Saunthararajah · 2022 · International Journal of Cancer
Epigenetic Reprogramming of Human Hepatoma Cells: A Low-Cost Option for Drug Metabolism Assessment
Luc Gailhouste, Lee Chuen Liew, Ken Yasukawa, Keitaro Hagiwara, Norihiko Iwazaki, Yasuhiro Yamada, Izuho Hatada, Takahiro Ochiya · 2017 · Cellular and Molecular Gastroenterology and Hepatology
Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis
Nazareno González, Antonela Sofía Asad, José Gómez Escalante, Jorge Armando Pena Agudelo, Alejandro J. Nicola Candia, Matías Garcia Fallit, Adriana Seilicovich, Marianela Candolfi · 2021 · Expert Opinion on Therapeutic Targets
In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation
Gemma L. Robinson, Beatrice Philip, Matthew R. Guthrie, James Eric Cox, James Robinson, Matthew W. VanBrocklin, Sheri L. Holmen · 2016 · Cancer Research Frontiers
Mechanism analysis and targeted therapy of IDH gene mutation in glioma
Xingyuan Ma · 2025 · American Journal of Cancer Research
IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment
Patricia D.B. Tiburcio, Bing Xiao, Yi Chai, Sydney Asper, Sheryl R. Tripp, David L. Gillespie, Randy L. Jensen, Eric L. Huang · 2018 · Oncotarget
Integrative multi‐omic analysis reveals neurodevelopmental gene dysregulation in CIC ‐knockout and IDH1 ‐mutant cells
Stephen Dongsoo Lee, Jungeun Song, Véronique Leblanc, Marco A. Marra · 2021 · The Journal of Pathology
The TET/5hmC mediated epigenetic landscape in glioma: From molecular mechanisms to therapeutic targeting and future perspectives
Jiarong He, Fei Peng, Ying Xu, Zhongyue Liu, Kai Su, Yang Zhou, Yugang Jiang, Ming Wang · 2026 · Pharmacological Research
Synergistic inhibitory effects of low‑dose decitabine in combination with bortezomib in the AML cell line Kasumi‑1
Vassiliki Mpakou, Aris Spathis, Anthi Bouhla, Efthimia Mpazani, Sotirios G. Papageorgiou, Konstantinos Gkontopoulos, Eirini Glezou, Thomas P. Thomopoulos, Periklis G. Foukas, Vasiliki Pappa · 2021 · Experimental and Therapeutic Medicine
Regulation of SPDEF expression by DNA methylation in advanced prostate cancer
Mousa Vatanmakanian, Joshua J. Steffan, Sweaty Koul, Augusto C. Ochoa, Lakshmi Shankar Chaturvedi, Hari K. Koul · 2023 · Frontiers in Endocrinology
Advances in molecular and imaging biomarkers in lower-grade gliomas
Alberto Pïcca, Francesco Bruno, Lucia Nichelli, Marc Sanson, Roberta Rudà · 2023 · Expert Review of Neurotherapeutics
Ultra-Low-Dose Decitabine Combined With Autologous Cytokine-Induced Killer Cells for Elderly Patients With Acute Myeloid Leukemia Transformed From Myelodysplastic Syndrome
Haitao Wang, Bo Yeun Yang, Xiao-Hua Chi, Lili Cai, Ruili Yu, Hongli Zhu, Shuai Tuo, Feng Zhang, Xuanchi Wang, Yang Yang et al. · 2014 · Clinical Therapeutics
IDH-Mutant Gliomas
Kensuke Tateishi, Tetsuya Yamamoto · 2019 · IntechOpen eBooks
A Comparative Study Between Tumor Blood Vessels and Dynamic Contrast-enhanced MRI for Identifying Isocitrate Dehydrogenase Gene 1 (IDH1) Mutation Status in Glioma
Shihui Li, Nanxi Shen, Di Wu, Ju Zhang, Jiaxuan Zhang, Jingjing Jiang, Wenzhen Zhu · 2022 · Current Medical Science
Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?
Franziska Maria Ippen, Howard Colman, Martin J. van den Bent, Priscilla Kaliopi Brastianos · 2018 · American Society of Clinical Oncology Educational Book
Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas
Alberto Pïcca, Anna Luisa Di Stefano, Marc Sanson · 2018 · Current Opinion in Neurology
Advances in the treatment of IDH-mutant gliomas
Chooyoung Baek, Alice Laurenge, Mehdi Touat · 2024 · Current Opinion in Neurology
Under explored epigenetic modulators: role in glioma chemotherapy
Yanhong Chen, Wenjing Zeng, Zhipeng Wen, Quan Cheng, Xiaoping Chen · 2018 · European Journal of Pharmacology
Current and emerging therapies in IDH-mutant glioma
Vihang Nakhate, Gilbert Youssef, Patrick Yung Wen · 2026 · Neurotherapeutics
DNMT1 drives glioma progression and modulates therapy response: A novel therapeutic target
Alkinoos A Armoundas, Christina Piperi · 2025 · European Journal of Medicinal Chemistry
Fucoidan: An Update on Function, Role in Human Health and Applications
Sharon Critelli, Marilena Celano · 2026 · Chemical Biology & Drug Design
Genetic Markers in Adult High-Grade Gliomas
Melike Pekmezci, Arie Perry · 2014 · Seminars in Radiation Oncology
The JmjC-domain protein NO66/RIOX-1 affects the balance between proliferation and maturation in acute myeloid leukemia
Weijia Yu, Christoph Lutz, Alwin Krämer, Marion S. Schmidt-Zachmann · 2021 · Experimental Cell Research
Orthotopic Transplantation of Human Paediatric High-Grade Glioma in Zebrafish Larvae
Susanna C. Larsson, Petronella Kettunen, Helena Carén · 2022 · Brain Sciences
Modulation of DNA/RNA Methylation Signaling Mediating Metabolic Homeostasis in Cancer
Pallawi Choubey, Harshdeep Kaur, Kushagra Bansal · 2022 · Sub-cellular biochemistry/Subcellular biochemistry
Perspectives on investigational drugs and immunotherapies for glioblastoma
Julie J. Miller, William T. Curry, Daniel P. Cahill, Jörg Dietrich · 2016 · Expert Opinion on Investigational Drugs
Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1 -mutant glioma
Alişan Kayabölen, Ebru Yilmaz, Gizem Nur Şahin, Fidan Seker-Polat, Ahmet Cingöz, Bekir Isik, Simge Acar, Hiroaki Wakimoto, Daniel P. Cahill, İhsan Solaroğlu et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
Enhancing demethylation-induced differentiation in IDH-mutant glioma
Julie J. Miller, Daniel P. Cahill, Isabel Arrillaga‐Romany · 2022 · Neuro-Oncology
Understanding the Crosstalk Between Epigenetics and Immunometabolism to Combat Cancer
Anuradha Seth, Susanta Kar · 2022 · Sub-cellular biochemistry/Subcellular biochemistry
Malignant glioma in L-2-Hydroxy Glutaric Aciduria: thorough molecular characterization of a case and literature review
Fleur Cordier, Pieter Wesseling, Bastiaan B.J. Tops, Lennart A. Kester, Pim J. French, Martin J. van den Bent, Felix E. Hinz, Eleonora Aronica, Kari-Anne Mariam Slot, Floor C. H. Abbink et al. · 2024 · Free Neuropathology
CPI203, a BET inhibitor, down-regulates a consistent set of DNA synthesis genes across a wide array of glioblastoma lines
Matthew C. Garrett, Troy Carnwath, Rebecca Albano, Yonghua Zhuang, Catherine A. Behrmann, Merissa Pemberton, Farah Barakat, Robert M. Lober, Mark Hoeprich, Anthony Joseph Paravati et al. · 2025 · PLoS ONE
Combining Epigenetic and Immunotherapy in Cancer: Molecular Mechanisms
Anna Meiliana, Andi Wijaya · 2023 · The Indonesian Biomedical Journal
Highlights from the Literature
Jason T. Huse, Roger Abounader, Benjamin W. Purow, Monika E. Hegi, Riccardo Soffietti, Kenneth Aldape · 2016 · Neuro-Oncology
2-Hydroxy-Glutarate 3-Dimensional Functional Spectroscopy in the Evaluation of Isocitrate Dehydrogenase–Mutant Glioma Response to Therapy
Kenan Alkhalili, Georgios Andrea Zenonos, Juan Carlos Fernandez-Miranda · 2016 · Neurosurgery